AI Summary
This content discusses the discovery of a preclinical candidate, AD1058, as a potential treatment for advanced malignancies. The compound is described as highly potent, selective, and capable of penetrating the blood-brain barrier. This suggests that AD1058 could be a promising ATR inhibitor for treating aggressive forms of cancer.